Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Kevin Mcculloch sold 15,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $8.49, for a total value of $127,350.00. Following the sale, the insider owned 1,639,208 shares in the company, valued at approximately $13,916,875.92. The trade was a 0.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kevin Mcculloch also recently made the following trade(s):
- On Monday, August 3rd, Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.02, for a total transaction of $120,300.00.
- On Wednesday, July 1st, Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total transaction of $722,700.00.
Xeris Biopharma Stock Performance
Shares of NASDAQ XERS traded down $0.01 during trading on Tuesday, reaching $8.43. 1,144,088 shares of the company traded hands, compared to its average volume of 1,849,041. The stock has a market cap of $1.54 billion, a P/E ratio of -76.64 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $10.08. The firm’s fifty day simple moving average is $8.32 and its 200 day simple moving average is $6.93. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00.
Hedge Funds Weigh In On Xeris Biopharma
Hedge funds and other institutional investors have recently made changes to their positions in the company. Walleye Capital LLC purchased a new stake in shares of Xeris Biopharma during the second quarter worth approximately $4,841,000. Rice Hall James & Associates LLC purchased a new position in Xeris Biopharma in the 1st quarter valued at $1,456,000. Janus Henderson Group PLC lifted its holdings in Xeris Biopharma by 322.8% in the 1st quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock valued at $1,713,000 after purchasing an additional 225,602 shares in the last quarter. Granahan Investment Management LLC boosted its stake in Xeris Biopharma by 249.4% during the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after purchasing an additional 873,236 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in Xeris Biopharma during the 1st quarter worth $1,204,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on XERS shares. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Barclays boosted their price target on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Finally, Wall Street Zen cut shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma has an average rating of “Hold” and an average price target of $12.00.
Check Out Our Latest Stock Analysis on XERS
Xeris Biopharma Company Profile
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Featured Articles
- Five stocks we like better than Xeris Biopharma
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
